NCT00610727 - Staccato Prochlorperazine Single Dose PK Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions

Migraine

Interventions

DRUG

Prochlorperazine 0.5 mg IV over 5 sec

IV Prochlorperazine for bioavailability

DRUG

Inhaled prochlorperazine 0.625 mg

Inhaled Staccato Prochlorperazine 0.625 mg

DRUG

Inhaled prochlorperazine 1.25 mg

Inhaled Staccato Prochlorperazine 1.25 mg

DRUG

Inhaled prochlorperazine 2.5 mg

Inhaled Staccato Prochlorperazine 2.5 mg

DRUG

Inhaled prochlorperazine 5 mg

InhaledStaccato Prochlorperazine 5 mg

DRUG

Inhaled prochlorperazine 10 mg

InhaledStaccato Prochlorperazine 10 mg

DRUG

Inhaled placebo

Inhaled Staccato Placebo (0 mg)

DRUG

Prochlorperazine 10 mg IV over 5 sec

Prochlorperazine 10 mg IV over 5 sec for patient qualification

Trial Locations (1)

PPD Phase I Clinic, Austin